Alector has confirmed that an alliance with GSK to develop two drug candidates for dementia has been terminated in the wake ...

Amgen has reacted with consternation to the news that treatment with its KRAS inhibitor Lumykras will no longer be funded in ...

Shares in AstraZeneca were trading down more than 8% this morning after it revealed that its transthyretin amyloidosis (ATTR) ...

B inhibitor Jascayd (nerandomilast) has been cleared as a twice-daily, oral therapy for adults with IPF as well as ...

Hengrui and Kailera have been vocal about positioning the drug as being capable of improving the clinical profile of existing ...

At the moment, many of the big AI systems used in drug discovery are closed-source, meaning they are proprietary and carry an ...

It’s exciting news in an orphan indication which currently lacks any approved treatment, and Dr Hans Lee, director of ...

In another big-ticket licensing deal with a Chinese biotech, AstraZeneca has claimed rights to a drug candidate for chronic ...

Vera Therapeutics has won FDA approval for Trutakna, a BAFF/APRIL inhibitor for IgA nephropathy (IgAN) that will compete with ...

The EU is asking for feedback on measures proposed by Sanofi to address concerns about a marketing campaign for a flu vaccine ...

Marcus Evans announces The Evolution Summit, taking place September 28-29, 2026, at Park Hyatt Aviara Resort, Golf Club & Spa ...

Just weeks after forming as a spinout from Endevica Bio, obesity drug developer Kalohexis has filed for an IPO, whilst ...